Cancer Vaccine Institute News

"We'd really like to see the science of oncology more, again through that lens of what is really going to make the difference for the patient in the next five years." That's the standard that Dr. Nora Disis is setting. In Episode 267 of Healthcare Unfiltered,  Dr. Disis, Director of the Cancer Vaccine Institute (CVI), Editor-In-Chief of Jama Oncology , and Deputy Editor of JAMA, shares her vision for the future of medical publishing with Dr. Chadi Nabhan. She discusses the ev

Last week, KING 5 News featured ongoing research at the Cancer Vaccine Institute (CVI) to develop COLOVAC , a preventive vaccine designed to stop colon cancer before it starts. The segment included interviews with CVI Director Dr. Nora Disis and Becky Bruhn, a Seattle resident whose recent cancerous polyp illustrates the importance of early detection and need for new prevention tools. Colon cancer remains one of the leading causes of cancer death in the United States, and rat

We are proud to announce that Dr. Nora Disis, Director of the UW Cancer Vaccine Institute (CVI) and Dr. Kiran Dhillon, Executive Director, have been selected to join the 2026 XPRIZE Global Visioneering Brain Trust in the Health domain. XPRIZE brings world-class innovators  together to tackle humanity’s greatest challenges through large-scale competitions that drive real-world impact. Their goal is to optimize wellness, advance personalized medicine, and drive scientific break

Dr. Denise Cecil, CVI Principal Scientist. PC: AP Photos Colon cancer is the second leading cause of cancer death in the United States, with diagnoses rising among adults under 55. In response, the Cancer Vaccine Institute (CVI) at UW Medicine is developing COLOVAC, a first-in-class vaccine designed to intercept colon cancer at its earliest stages, offering hope to those at the highest risk. Rising Colon Cancer Risk Colon cancer remains one of the most consequential cancers o

Photo Credits: Fred Hutch Dr. Natasha (Tasha) Hunter , Cancer Vaccine Institute Director of Clinical Trials, has been selected as the recipient of the 2026 Athena Endowed Award for Excellence in Breast Cancer Research. The Athena Award was established to recognize an early career researcher making the greatest contribution during the past year toward advancing research to improve the prevention, detection, diagnosis and/or treatment of breast cancer. Read more about Dr. Hunte